An attenuated immune response is sufficient to enhance cognition in an Alzheimer's Disease mouse model immunized with amyloid- derivatives
An attenuated immune response is sufficient to enhance cognition in an Alzheimer's Disease mouse model immunized with amyloid- derivatives
Immunization with amyloid-? (A?) 1-42 has been shown to reduce amyloid burden and improve cognition in Alzheimer's disease (AD) model mice. In a human trial, possible cognitive benefit was found but in association with significant toxicity in a minority of patients. We proposed that immunization with nonfibrillogenic A? derivatives is much less likely to produce toxicity and have previously shown that one such derivative (K6A?1-30) can reduce amyloid burden in mice to a similar extent as A?1-42. Here, we immunized AD model mice (Tg2576) with A?1-30[E18E19] or with K6A?1-30[E18E19]. These peptides were designed to be nontoxic and to produce less T-cell response, which has been linked to toxicity. K6A?1-30[E18E19] induced primarily an IgM response, whereas A?1-30[E18E19] induced an IgG titer that was lower than previously seen with K6A?1-30 or A?1-42. However, both treated animal groups performed better than Tg controls in the radial arm maze. Amyloid burden was similar in A?1-30[E18E19]-vaccinated mice and their Tg controls, whereas the number of medium and small sized plaques was reduced (29-34%) in K6A?1-30[E18E19]-immunized mice compared with Tg controls. Amyloid burden in these mice correlated inversely with plasma IgM levels. The cognitive benefit and amyloid reduction in the K6A?1-30[E18E19]-vaccinated mice are likely to be related to peripheral clearance of A?, because IgM does not cross the blood-brain barrier because of its large size. Our results indicate that these nontoxic A? derivatives produce an attenuated antibody response, which is less likely to be associated with negative side effects while having cognitive benefits.
mamyloid-?, immunization, transgenic mice, behavior
6277-6282
Sigurdsson, E.M.
9e00ebbc-aec3-4fd2-a4e1-f0696f5fbf00
Knudsen, Elin
0fb87703-707f-4939-8c65-5b3073a3e8ba
Asuni, Ayodeji A.
b1412b1b-9794-4705-aada-aed5d3da038f
Fitzer-Attas, Cheryl
8eedc07f-c5ec-4f3c-8894-05e681af97a4
Sage, Daniel
80462d6b-8ccd-4ffb-9e75-0b24d21fc317
Quartermain, David
b86503e8-f88e-4869-b9bc-971afe498ff9
Goni, Fernando
d291ee2a-348c-4488-94f4-f47320d21323
Frangione, Blas
361865d7-4f64-4112-b269-52932d45d376
Wisniewski, Thomas
2b01413e-928d-4c40-9a02-0c87d90942d0
14 July 2004
Sigurdsson, E.M.
9e00ebbc-aec3-4fd2-a4e1-f0696f5fbf00
Knudsen, Elin
0fb87703-707f-4939-8c65-5b3073a3e8ba
Asuni, Ayodeji A.
b1412b1b-9794-4705-aada-aed5d3da038f
Fitzer-Attas, Cheryl
8eedc07f-c5ec-4f3c-8894-05e681af97a4
Sage, Daniel
80462d6b-8ccd-4ffb-9e75-0b24d21fc317
Quartermain, David
b86503e8-f88e-4869-b9bc-971afe498ff9
Goni, Fernando
d291ee2a-348c-4488-94f4-f47320d21323
Frangione, Blas
361865d7-4f64-4112-b269-52932d45d376
Wisniewski, Thomas
2b01413e-928d-4c40-9a02-0c87d90942d0
Sigurdsson, E.M., Knudsen, Elin, Asuni, Ayodeji A., Fitzer-Attas, Cheryl, Sage, Daniel, Quartermain, David, Goni, Fernando, Frangione, Blas and Wisniewski, Thomas
(2004)
An attenuated immune response is sufficient to enhance cognition in an Alzheimer's Disease mouse model immunized with amyloid- derivatives.
Journal of Neuroscience, 24 (28), .
(doi:10.1523/Jneurosci.1344-04.2004).
Abstract
Immunization with amyloid-? (A?) 1-42 has been shown to reduce amyloid burden and improve cognition in Alzheimer's disease (AD) model mice. In a human trial, possible cognitive benefit was found but in association with significant toxicity in a minority of patients. We proposed that immunization with nonfibrillogenic A? derivatives is much less likely to produce toxicity and have previously shown that one such derivative (K6A?1-30) can reduce amyloid burden in mice to a similar extent as A?1-42. Here, we immunized AD model mice (Tg2576) with A?1-30[E18E19] or with K6A?1-30[E18E19]. These peptides were designed to be nontoxic and to produce less T-cell response, which has been linked to toxicity. K6A?1-30[E18E19] induced primarily an IgM response, whereas A?1-30[E18E19] induced an IgG titer that was lower than previously seen with K6A?1-30 or A?1-42. However, both treated animal groups performed better than Tg controls in the radial arm maze. Amyloid burden was similar in A?1-30[E18E19]-vaccinated mice and their Tg controls, whereas the number of medium and small sized plaques was reduced (29-34%) in K6A?1-30[E18E19]-immunized mice compared with Tg controls. Amyloid burden in these mice correlated inversely with plasma IgM levels. The cognitive benefit and amyloid reduction in the K6A?1-30[E18E19]-vaccinated mice are likely to be related to peripheral clearance of A?, because IgM does not cross the blood-brain barrier because of its large size. Our results indicate that these nontoxic A? derivatives produce an attenuated antibody response, which is less likely to be associated with negative side effects while having cognitive benefits.
This record has no associated files available for download.
More information
Published date: 14 July 2004
Keywords:
mamyloid-?, immunization, transgenic mice, behavior
Organisations:
Centre for Biological Sciences
Identifiers
Local EPrints ID: 345525
URI: http://eprints.soton.ac.uk/id/eprint/345525
PURE UUID: 95888902-29cd-4bcb-8919-650e750456fd
Catalogue record
Date deposited: 25 Feb 2013 15:56
Last modified: 14 Mar 2024 12:26
Export record
Altmetrics
Contributors
Author:
E.M. Sigurdsson
Author:
Elin Knudsen
Author:
Ayodeji A. Asuni
Author:
Cheryl Fitzer-Attas
Author:
Daniel Sage
Author:
David Quartermain
Author:
Fernando Goni
Author:
Blas Frangione
Author:
Thomas Wisniewski
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics